Wedbush Reiterates “Outperform” Rating for Tyra Biosciences (NASDAQ:TYRA)

Tyra Biosciences (NASDAQ:TYRA)‘s stock had its “outperform” rating restated by equities researchers at Wedbush in a report released on Friday,RTT News reports. They currently have a $30.00 target price on the stock. Wedbush’s price objective points to a potential upside of 207.06% from the stock’s previous close. Wedbush also issued estimates for Tyra Biosciences’ FY2029 earnings at ($0.91) EPS.

Other equities analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 target price on shares of Tyra Biosciences in a research report on Tuesday, February 18th. UBS Group started coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They set a “buy” rating and a $28.00 price target on the stock. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, Tyra Biosciences presently has a consensus rating of “Buy” and a consensus price target of $30.83.

Tyra Biosciences Trading Up 1.1 %

NASDAQ:TYRA opened at $9.77 on Friday. The firm has a market capitalization of $494.39 million, a PE ratio of -6.07 and a beta of 1.09. Tyra Biosciences has a 1 year low of $9.49 and a 1 year high of $29.60. The firm’s fifty day simple moving average is $12.46 and its 200 day simple moving average is $16.33.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.05. As a group, analysts anticipate that Tyra Biosciences will post -1.57 EPS for the current fiscal year.

Insider Transactions at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 5,401 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the transaction, the director now owns 443,885 shares in the company, valued at approximately $6,107,857.60. The trade was a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders have sold 21,998 shares of company stock valued at $344,818. 15.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TYRA. KLP Kapitalforvaltning AS acquired a new stake in shares of Tyra Biosciences in the 4th quarter valued at $31,000. US Bancorp DE bought a new position in shares of Tyra Biosciences in the 4th quarter valued at about $50,000. BNP Paribas Financial Markets bought a new position in shares of Tyra Biosciences in the 4th quarter valued at about $60,000. Aquatic Capital Management LLC acquired a new stake in shares of Tyra Biosciences during the 4th quarter worth approximately $64,000. Finally, Wells Fargo & Company MN raised its stake in shares of Tyra Biosciences by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after buying an additional 3,236 shares during the last quarter. 84.14% of the stock is owned by institutional investors.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.